{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:36:15Z","timestamp":1777307775621,"version":"3.51.4"},"reference-count":41,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PPA"],"DOI":"10.2147\/ppa.s576524","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:45:13Z","timestamp":1777304713000},"page":"1-15","source":"Crossref","is-referenced-by-count":0,"title":["iPREFER: Patients\u2019 Experiences and Preference of Treatment for Multiple Myeloma Following Multiple Lines of Treatment \u2013 A Qualitative Study"],"prefix":"10.2147","volume":"Volume 20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2978-2272","authenticated-orcid":true,"given":"Melissa","family":"Perry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9726-2246","authenticated-orcid":true,"given":"Ramsay","family":"Lochhead Devaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0995-8309","authenticated-orcid":true,"given":"Kate","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fay","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9026-1789","authenticated-orcid":true,"given":"Sally","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4]]},"reference":[{"key":"ref1","unstructured":"Cancer Research UK. Myeloma incidence statistics; 2024. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma\/incidence#heading-Zero. Accessed November 4, 2024."},{"key":"ref2","unstructured":"Myeloma UK. What is myeloma? 2023. Available from: https:\/\/www.myeloma.org.uk\/understanding-myeloma\/what-is-myeloma\/. Accessed October 30, 2024."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.7861\/clinmed.2022-0144","volume":"22","author":"Nandra","year":"2022","journal-title":"Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.clml.2017.06.021","volume":"17","author":"Gonz\u00e1lez-Calle","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref5","unstructured":"Myeloma UK. Treating myeloma; 2023. Available from: https:\/\/www.myeloma.org.uk\/understanding-myeloma\/treating-myeloma\/. Accessed October 30, 2024."},{"key":"ref6","unstructured":"Myeloma UK. Treatment for relapsed myeloma; 2024. Available from: https:\/\/www.myeloma.org.uk\/understanding-myeloma\/treating-myeloma\/treatment-for-relapsed-myeloma\/. Accessed October 30, 2024."},{"key":"ref7","unstructured":"Cancer Research UK. Treatment options for myeloma; 2023. Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/myeloma\/treatment\/treatment-decisions. Accessed November 8, 2024."},{"key":"ref8","unstructured":"National Institute for Health and Care Excellence. Lenalidomide plus dexamethasone for previously untreated multiple myeloma; 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ta587\/chapter\/2-Information-about-lenalidomide. Accessed March 6, 2026."},{"key":"ref9","unstructured":"Janssen-Cilag Ltd. DARZALEX 1800 mg solution for injection PIL; 2025. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/11488\/pil. Accessed March 6, 2026."},{"key":"ref10","unstructured":"Janssen-Cilag Ltd. DARZALEX 20 mg\/mL concentrate for solution for infusion PIL; 2026. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/7250\/pil. Accessed March 6, 2026."},{"key":"ref11","unstructured":"ClinicalTrials.gov. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO); 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06158841. Accessed February 20, 2026."},{"key":"ref12","unstructured":"ClinicalTrials.gov. MagnetisMM-32: a study to learn about the study medicine called elranatamab in people with multiple myeloma (MM) that has come back after taking other treatments (including prior treatment with an anti-CD38 antibody and lenalidomide); 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06152575. Accessed February 20, 2026."},{"key":"ref13","unstructured":"ClinicalTrials.gov. Study to evaluate CCS1477 (Inobrodib) in haematological malignancies; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04068597. Accessed February 20, 2026."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/23743735221079133","volume":"9","author":"Rubins","year":"2022","journal-title":"J Patient Exp"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s11136-019-02392-6","volume":"29","author":"LeBlanc","year":"2020","journal-title":"Qual Life Res"},{"key":"ref16","volume-title":"Understanding Multiple Myeloma","year":"2019"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"Nucci","year":"2009","journal-title":"Clinl Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2174\/1568009617666170214104426","volume":"17","author":"Raza","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s11899-018-0443-0","volume":"13","author":"McCullough","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"ref20","unstructured":"Myeloma UK HCP Hub. Financial concerns; 2024. Available from: https:\/\/hcp.myeloma.org.uk\/courses\/myeloma-nurse-learning-programme\/lessons\/module-10-living-well-with-myeloma\/topics\/financial-concerns\/. Accessed November 5, 2024."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e39068","DOI":"10.2196\/39068","volume":"8","author":"Lyall","year":"2022","journal-title":"JMIR Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00520-009-0793-1","volume":"19","author":"Molassiotis","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40271-021-00501-7","volume":"14","author":"He","year":"2021","journal-title":"Patient"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-022-10458-x","volume":"23","author":"Dombeck","year":"2023","journal-title":"BMC Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1200\/JOP.2016.019729","volume":"13","author":"Jacobs","year":"2017","journal-title":"J Oncol Pract"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.2147\/PPA.S183187","volume":"12","author":"Wilke","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/ejh.14180","volume":"112","author":"Ayto","year":"2024","journal-title":"Eur J Haematol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/fon-2021-0260","volume":"18","author":"Dhakal","year":"2022","journal-title":"Future Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/PPA.S106629","volume":"10","author":"Eek","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2023.1271657","volume":"10","author":"Thomas","year":"2023","journal-title":"Front Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1182\/blood-2018-99-112921","volume":"132","author":"McKay","year":"2018","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"100062","DOI":"10.1016\/j.cgpj.2025.100062","volume":"2","author":"Xu","year":"2025","journal-title":"Chin Gen Pract"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s41669-019-00184-9","volume":"4","author":"Rifkin","year":"2020","journal-title":"Pharmacoecon Open"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"Sekhon","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"Malterud","year":"2016","journal-title":"Qual Health Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"114523","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc Sci Med"},{"key":"ref37","unstructured":"National Institute for Health and Care Excellence (NICE). Myeloma: diagnosis and management (NG35); 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ng35. Accessed February 20, 2026."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5467-x","volume":"19","author":"Parsons","year":"2019","journal-title":"BMC Cancer"},{"key":"ref40","unstructured":"NHS England. Precision medicine; 2020. Available from: https:\/\/transform.england.nhs.uk\/ai-lab\/explore-all-resources\/understand-ai\/precision-medicine\/. Accessed November 1, 2024."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/JMDH.S104807","volume":"9","author":"Althubaiti","year":"2016","journal-title":"J Multidiscip Healthc"}],"container-title":["Patient Preference and Adherence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/114576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/114576","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:45:23Z","timestamp":1777304723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/iprefer-patients-experiences-and-preference-of-treatment-for-multiple--peer-reviewed-fulltext-article-PPA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":41,"URL":"https:\/\/doi.org\/10.2147\/ppa.s576524","relation":{},"ISSN":["1177-889X"],"issn-type":[{"value":"1177-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}